Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells

Meehyun Ko, Sangeun Jeon, Wang Shick Ryu, Seungtaek Kim

Research output: Contribution to journalArticle

Abstract

Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC50 = 0.0022 µM).

Original languageEnglish
JournalJournal of Medical Virology
DOIs
Publication statusAccepted/In press - 2020

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells'. Together they form a unique fingerprint.

  • Cite this